iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

NCT02802943 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
56
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Hospital Tuebingen

Collaborators